BioVac Nepal, has been nominated as a “Company to Watch out in 2022” in the “Asia Pacific Vaccine Excellence Awards 2021”. The prestigious award is an annual event that recognizes exceptional Asian vaccine manufacturers and their accomplished achievements. Despite the COVID-19 pandemic, the industry has been resilient with its continued R&D excellence. The event honors the top vaccine and supply chain experts, organizations, and features the industry leaders and garners a lot of attention from the industry, where latest technologies and the best practices in R&D and manufacturing are featured. Each year, the Awards event applauds the extraordinary leaders and trendsetters of today and inspires the innovators of tomorrow.

BioVac Nepal, a portfolio company of One to Watch is a poultry vaccine research, development and manufacturing company based in Nepal which aims to create long term, sustainable vaccines to meet the local and international demand. Using the latest technologies, BioVac Nepal studies disease burden and dynamics, evaluates novel vaccine targets and manufactures vaccines that have high efficacy rates and are cost effective. 

In Nepal, farmers have been using thermo-unstable Newcastle Disease Virus (NDV) vaccines imported primarily from India, Italy, and South Korea. Due to lack of good transportation system in rural areas, it is challenging to make these vaccines accessible in such areas as it requires cold chain storage. This is the gap that BioVac Nepal caters to with its thermostable I2 vaccines. One to Watch invested in Biovac Nepal in 2018 to support them in their mission to develop cold-chain free NDV vaccines and increase its access to rural communities of Nepal. Currently, BioVac Nepal is the only domestic producer and distributor of the I-2 strain of NDV vaccine.

Support Biovac Nepal by casting your vote at: https://lnkd.in/dbmyPAC8